10.09.2020 • News

JM and KBR Link on Ammonia-Methanol Process

UK specialty chemicals and sustainable technologies company Johnson Matthey (JM) and US engineering and construction contractor KBR have entered into an alliance to license a “ground-breaking” ammonia-methanol co-production process.

The process combines JM’s methanol and KBR’s proprietary Purifier ammonia technologies. The companies said co-production of methanol and ammonia in a single plant eliminates duplication of equipment compared to two stand-alone plants, reducing capital expenditure. In addition, synergies between the two technologies, such as shared utilities, reduce a plant’s environmental impact and operating costs as well as energy consumption.

The process also provides the flexibility to optimize production and adjust to opportunities within the marketplace, as opposed to separate plants tied to one dedicated product.

“Methanol and ammonia hold great promise for continued energy and fuels transition to a greener world,” said John Gordon, JM’s managing director. “Our partnership with KBR takes ammonia-methanol production to the next step with a single point license that delivers innovative operational agility to meet ever changing market demand.”

Ammonia is primarily used to produce urea for fertilizer, with methanol and its derivatives mainly used to produce formaldehyde, acrylic plastics, synthetic fabrics, adhesives, paints, and other ingredients in pharmaceuticals and agrochemicals.

KBR has licensed, engineered or built nearly 250 ammonia plants worldwide since the 1960s while JM has licensed over 100 grassroots methanol plants in more than 45 years.

 

Author: Elaine Burridge, Freelance Journalist

Johnson Matthey and KBR have formed an alliance to license an ammonia-methanol...
Johnson Matthey and KBR have formed an alliance to license an ammonia-methanol co-production process. The process combines JM’s methanol and KBR’s proprietary Purifier ammonia technologies and will lead to capital and operational cost savings as well as lower energy use. © Pexels

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read